Title: Nationwide surveillance of methicillin-resistant *Staphylococcus aureus* isolated from

bloodstream infections in Japan

Short title: Surveillance of MRSA isolated from BSI in Japan

Authors: Norihito Kaku[1,3*], Daisuke Sasaki[2], Kenji Ota[1,2], Taiga Miyazaki[4], Katsunori

Yanagihara[1,2]

Affiliations:

[1]Department of Laboratory Medicine, Nagasaki University Graduate School of Biomedical

Sciences, Nagasaki City, Nagasaki, Japan

[2]Department of Laboratory Medicine, Nagasaki University Hospital, Nagasaki City, Nagasaki,

Japan

[3]Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor,

Michigan, United States

[4]Division of Respirology, Rheumatology, Infectious Diseases, and Neurology, Department of

Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki City, Miyazaki, Japan

[*]**Corresponding Author:** Norihito Kaku

1-7-1 Sakamoto, Nagasaki City, Nagasaki, Japan 852-8501

Email: norihitk@gmail.com

Tel: +81-95-819-7574 Fax: +81-95-819-7422

Abstract

Objectives: Some single-center studies have reported that methicillin-resistant Staphylococcus

aureus (MRSA) carrying the staphylococcal cassette chromosome mec (SCCmec) type IV has

been increasing in bloodstream infections (BSIs) in Japan. Therefore, we conducted nationwide

surveillance for MRSA BSI to verify that there is a change all over Japan.

Methods: We recruited 51 Japanese hospitals from the Japanese Association for Infectious

Diseases. MRSA strains, which were detected in two or more sets of blood, were collected

between January and September 2019. They were analyzed by antimicrobial susceptibility

testing at Nagasaki University Hospital. Whole-genome sequencing was also performed to

determine SCCmec typing and multilocus typing and detect drug-resistance and virulence genes.

Results: 270 MRSA strains were collected from 45 hospitals. The major clones were ST8 with

SCCmec type IV (ST8-IV) (30.7%), ST1-IV (29.6%), ST2725-IV (9.5%), ST764-II (8.1%), and

ST5-II (7.8%). However, there were regional differences among the most major clones. The

most common clones in western, eastern, and northern Japan were ST1-IV, ST8-IV, and ST5-II,

respectively. ST8-IV, ST1-IV, and ST2725-IV exhibited lower drug resistance against

clindamycin and minocycline than ST764-II and ST5-II, but erm(A) was detected in 93.8% and

100% of ST1-IV and ST2725-IV, respectively. Based on drug-resistance and virulence genes,

characteristics of ST8-IV were different from those of ST1-IV and ST2725. In addition, the two

major types were expected to be ST8-IV.

Conclusions: This study revealed that SCCmec type IV clones replaced SCCmec type II in

MRSA BSI. In addition, three main types of SCCmec type IV clones have spread throughout

Japan.

Introduction

Methicillin-resistant *Staphylococcus aureus* (MRSA) is an important drug-resistant pathogen in bloodstream infections (BSIs) because *S. aureus,* including MRSA, is the second-most frequently encountered pathogen in both community- and hospital-onset BSI [1]. The percentage of patients with BSIs involving MRSA increased from 22% in 1995 to 57% in 2001 [2]. However, the incidence of MRSA BSIs has been decreasing since the middle of the 2000s through various infection control efforts [3]. However, a new threat involves the spread of community-associated MRSA (CA-MRSA), represented by USA300 strains. CA-MRSA strains carrying staphylococcal cassette chromosome *mec* (SCC*mec*) types IV or V have different characteristics than I, II, or III. CA-MRSA strains are more susceptible to antimicrobial agents such as fluoroquinolones, macrolides, lincosamides, and aminoglycosides; moreover, they sometimes carry Panton-Valentine leucocidin (PVL), which causes skin and soft-tissue infections and necrotizing pneumonia [4]. In Japan, sequence type (ST) 5 carrying SCC*mec* type II, represented by the New York/Japan clone, has been the most common clone in MRSA BSIs [5]. However, the proportion of SCC*mec* type II has been decreasing, while that of SCC*mec* type IV has been increasing in MRSA BSIs [6,7]. On the other hand, most SCC*mec* type IV strains in Japan lack PVL [6–8]. However, since these data were obtained from a single institution, the molecular epidemiology and characteristics of MRSA isolated from BSIs in Japan are unclear. In this study, we collected MRSA isolates from patients with BSIs throughout Japan in 2019 and performed antimicrobial susceptibility testing and whole-genome sequencing to reveal the strain characteristics of these MRSA isolates.

Methods

Study design

We recruited participating medical institutions through a mailing list obtained from the Japanese Association for Infectious Diseases in December 2018; 51 Japanese hospitals were recruited. MRSA strains detected in two or more sets of blood cultures at the same time were collected at each hospital between January 22 and September 30, 2019. No MRSA strains met the criteria in the six hospitals. Eventually, 274 strains collected from 45 hospitals were analyzed at Nagasaki University Hospital. Four strains were excluded from the analysis because they were identified as methicillin-sensitive *Staphylococcus aureus* at Nagasaki University Hospital (Supplementary Fig 1A). Finally, the remaining 270 strains were analyzed (Supplementary Fig 1B). They were stored in Microbank (Iwaki & Co., Ltd., Tokyo, Japan) at -80°C and transferred to Nagasaki University Hospital. The following data regarding MRSA strains were collected from the participating medical institutions: blood culture collection location (outpatient or inpatient) and day following hospitalization on which blood cultures were collected.

Antimicrobial susceptibility testing

The minimum inhibitory concentrations (MICs) were determined by broth microdilution testing using Dry Plate Eiken (Eiken, Tokyo, Japan) according to the manufacturer's instructions. MIC_{50} and MIC_{90} values were calculated as previously reported [9]. Antimicrobial susceptibility was measured according to Clinical and Laboratory Standards Institute guidelines (CLSI M100-Ed31) [10] and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) v.11.0 [11].

Whole-genome sequencing (WGS)

All procedures were performed according to the manufacturers' instructions. DNA was

extracted from MRSA strains using a Quick-DNA Fungal/Bacterial Kit (Zymo Research, Irvine,

CA, USA). DNA libraries for sequencing were generated using the Invitrogen Collibri ES DNA

Library Prep Kit for Illumina (A38607096, ThermoFisher Scientific, Waltham, MA, USA), and

sequencing was performed on a MiSeq system (Illumina, San Diego, CA, USA) using MiSeq

Reagent kit v. 3 (600 cycles) (Illumina).

Sequence analysis

Multilocus sequence typing (MLST) and detection of antimicrobial resistance genes in

ResFinder were performed using the CLC Genomics Workbench and Microbial Genomics

Modules (QIAGEN N. V., Venlo, Netherlands). SCC*mec* types were determined using

SCC*mec*Finder v.1.2 (https://cge.cbs.dtu.dk/services/SCCmecFinder/) [12]. Virulence genes

were detected using VirulenceFinder v.2.0.3 (https://cge.cbs.dtu.dk/services/VirulenceFinder/,

software v.2.0.3, database v.2020-05-29) [13,14].

Statistical analysis

All statistical analyses were performed using R software (v. 4.0.3; R Foundation for Statistical

Computing, Vienna, Austria). Fisher's exact test with Bonferroni correction was used to compare

categorical variables. The statistical significance level was set at $P < 0.05$. P values are listed in

Table S2.

Ethics

The Ethics Committee approved this study of Nagasaki University Hospital (19012123).

MRSA strains were anonymized and individually numbered when they were isolated from blood

cultures. All data and samples were fully anonymized before being sent to Nagasaki University

Hospital. The Ethics Committee of Nagasaki University Hospital waived requirements for

informed consent.

Data availability

Raw data were generated at Nagasaki University Hospital. The derived data supporting the

findings of this study are presented in this paper. WGS data reported in this study are available in

the DDBJ Sequence Read Archive (https://www.ddbj.nig.ac.jp/dra/index-e.html) under accession

number DRA013058.

Results

Sequence and SCCmec typing

Among 270 MRSA strains isolated from BSIs, the percentages of SCC*mec* types I, II, IV, V,

and IX were 1.9%, 18.5%, 77.4%, 1.9%, and 0.4%, respectively (Table S1). The major clone was

ST8 with SCC*mec* type IV (ST8-IV) (30.7%), ST1 with SCC*mec* type IV (ST1-IV) (29.6%),

ST2725 with SCC*mec* type IV (ST2725-IV) (9.5%), ST764 with SCC*mec* type II (ST764-II)

(8.1%), and ST5 with SCC*mec* type II (ST5-II) (7.8%) in Japan as a whole (Fig. 1A). However,

there were regional differences among major clones. The most common clones in western Japan,

eastern Japan, and northern Japan were ST1-IV, ST8-IV, ST5-II, and ST764-II, respectively (Fig.

1B). The characteristics of the major clones are listed in Table 1. The percentages of hospital-

acquired BSIs detected from samples obtained 48 hours after hospitalization, involving ST1-IV,

ST2725-IV, ST8-IV, ST5-II, and ST764 were 62.5%, 61.5%, 60.2%, 71.4%, 72.7%, respectively.

There were no significant differences in patient backgrounds among the clones (Table S2).

Antimicrobial susceptibility

Drug resistance rates calculated using the CLSI/EUCAST criteria are shown in Table 1. The

drug resistance rates for anti-MRSA agents were very low in all clones. However, for some

antimicrobial agents, there were significant differences among the clones. The drug resistance

rate for levofloxacin in both CLSI and EUCAST criteria in ST8-IV was significantly lower than

that of other clones ($p < 0.001$). The drug resistance rates for clindamycin for ST8-IV, ST1-IV,

and ST2725-IV were significantly lower than ST5-II and ST764-II ($p < 0.05$). In addition, the

drug resistance rate for clindamycin in ST1-IV and ST2725-IV was significantly lower than that

for ST8-IV ($p < 0.001$). The drug resistance rates for minocycline in EUCAST criteria in ST8-IV,

ST1-IV, and ST2725-IV were significantly lower than those of ST5-II and ST764-II ($p < 0.05$).

There were differences among the major clones in the MICs for beta-lactams (Table 2). Both

MIC_{50} and MIC_{90} for cefazoline, imipenem, and meropenem were lower in ST8-IV, ST1-IV, and

ST2725-IV than in ST5-II and ST764-II. These differences were particularly pronounced for

imipenem. The MIC_{90} for imipenem was ≤ 0.25, ≤ 0.25, and 0.5, respectively, in ST8-IV, ST1-

IV, and ST2725-IV, respectively, whereas it was ≥ 32 in both ST5-II and ST764-II.

Drug-resistance genes

Table 3 shows the positive rate for drug-resistance genes in each clone. Almost all major

clones carried aminoglycoside-resistance genes. However, specific aminoglycoside-resistance

genes differed among the major clones; for example, the positive rate for *ant(9)-Ia* for ST8-IV

was significantly lower than for other clones (p <0.001). The positive rate for the macrolide-

resistant gene *erm(A)* for ST8-IV was also significantly lower than for other clones (p <0.001).

In ST764-II, the positive rate for *blaZ* was significantly lower than for other clones (p <0.001),

whereas that for the fosfomycin-resistance gene was significantly higher than for other clones (p

<0.05). The positive rate for the tetracycline-resistance gene was significantly higher for ST5-II

and ST764-II than for ST8-IV, ST1-IV, and ST2725-IV (p < 0.05).

Virulence genes

Table 4 shows the positive rate for virulence genes in each clone. Almost all strains carried

exoenzyme genes, such as *aur*, *splA*, *and splB*. Although > 90% of the strains in ST1-IV and

ST2725-IV also carried *splE*, no strain in ST5-II and ST764-II carried it. In terms of toxins,

almost all strains carried *hlgA, hlgB, hlgC, LukD,* and *LukE*. Only five (6.0%) strains in ST8-IV

carried *LukF-PV*. CC1-IV, composed of ST1-IV and ST2725-IV, whereas CC5-II, composed of

ST5-II and ST764-II, had unique virulence genes. CC1-IV carried *sea*, *seh*, *sek*, and *seq*, whereas

CC5-II carried *sec, sei, sem, sen, seo,* and *seu*. However, there were some differences between

ST5-II and ST764-II; ST5-II carried *sec, sel,* and *tst* more frequently than ST764-II. For other

virulence genes, the arginine catabolic mobile element (ACME) was detected in 1.3%, 6.0%, and

31.8% for ST1-IV, ST8-IV, and ST765-II, respectively.

Discussion

The most common MRSA BSI clone in Japan was ST8-IV, closely followed by ST1-IV. In

contrast, ST5-II, which had been the most prevalent in Japan [5], ranked fifth, representing only

7.8%. A previous Japanese study, which analyzed 151 MRSA strains isolated from blood

cultures from 53 medical institutions in 2011, reported that the percentage of SCC*mec* type IV

was only 19.9%, whereas that of SCC*mec* type II was 75.6% [15]. However, a previous study

from Tokyo, in the Kanto region, reported that the relative abundances of SCC*mec* types II and

IV had reversed between 2015 and 2017, with SCC*mec* type IV the most prevalent, comprising

73.5% of MRSA BSI cases [7]. Therefore, although participating medical institutions and

analytic methods differed between earlier surveillance programs and this study [15], our data

indicated that ST8-IV and ST1-IV have replaced ST5-II in MRSA BSIs in Japan. However, there

were regional differences among the major clones. The most common clones in Western, Eastern,

and Northern Japan were ST8-IV, ST1-IV, ST5-II, and ST764-II, respectively. The most

common clone in northern Japan, in the Hokkaido region, was very different from other regions,

and the percentage of SCC*mec* type II was 71.4%. This is similar to the surveillance results

conducted in the Hokkaido region between 2017 and 2019 [16], although the number of medical

institutions that participated in the Hokkaido region in this study was only two. Thus, there may

be regional differences in the spread of ST8-IV and ST1-IV.

We observed differences among the major clones in terms of drug resistance. In antimicrobial

susceptibility testing, SCC*mec* type IV (ST8-IV, ST1-IV, and ST2725-IV) exhibited a

significantly lower resistance rate for clindamycin and minocycline than SCC*mec* type II of ST5-

II and ST764-II. The resistance rate for clindamycin was almost the same as the *erm(A)* gene

retention rate in ST8-IV, whereas the resistance rate for clindamycin was much lower than the

erm(A) gene retention rate in ST1-IV and ST2725. Since the *erm (A)* gene is related to inducible

clindamycin resistance [17], these results indicated that clindamycin should not be used to treat

ST1-IV and ST2725-IV infections even if a strain is sensitive to clindamycin in antimicrobial

susceptibility testing. In contrast, the drug-resistance rate for minocycline in the EUCAST

criteria was almost the same as the positive rate for the tetracycline resistance gene. SCC*mec*

type IV also showed lower MIC_{50} and MIC_{90} values for cefazolin, imipenem, and meropenem

than did SCC*mec* type II. This result was similar to a previous study [15]. Since beta-lactams

exhibit a synergic effect in combination with anti-MRSA agents in several studies [18,19], beta-

lactams might be considered to treat MRSA BSI caused by SCC*mec* type IV in combination with

anti-MRSA agents.

Almost all strains involving all the major clones carried *aur*, *splA, splB*, *hlgA, hlgB, hlgC,*

LukD, LukE, sak, and *scn*. ST1-IV and ST2725-IV, both of which are CC1-IV, had a similar

pattern of virulence genes. CC1-IV carried *splE, sea, seh, sek,* and *seq* more frequently than the

other clones. Since they also had a similar complement of drug resistance genes, there might be

no need to distinguish between ST1-IV and ST2725-IV in Japan. At the clonal complex level,

CC1-IV was the most abundant clone (39.3%). However, since no strain carried *Luk/*PV and

only one strain carried ACME in CC1-IV, they differed from USA-400. Several Japanese studies

have reported the same characteristics for CC1-IV [20,21]. In addition, *Luk/PV*-negative CC1-IV

has been reported in Europe and Australia [22,23]. The characteristics of CC1-IV in this study

and previous Japanese studies differ from those of European *Luk/PV*-negative CC1-IV regarding

virulence genes [23], whereas Japanese CC1-IV have a similar pattern to *Luk/PV*-negative CC1-

IV in Australia [22]. However, there exists a difference in macrolide-resistant genes between

Japan and Australia. These results indicate that CC1-IV has evolved and spread independently in

Japan. ST5-II and ST764-II, both of which are CC5-II, also had a similar pattern of virulence

genes, but there were significant differences between them. ST5-II carried *sec, sel,* and *tst* more

frequently than ST764-II. They also had different drug resistance genes, such as *aaD*, *fosD*, *and*

tet(S/M*)*. Since the spread of ST764-II among elderly Japanese in long-term care facilities in

Japan [24], the change in the ratio of CC5-II should be carefully monitored.

ST8-IV was the most frequently detected clone in this study, but it carried diverse virulence

genes. The positive rate for *sec* and *tst* was 44.6%, with one clone carrying both *LukF/PV* and

ACME. The *LukF/*PV-negative ST8 clone CA-MRSA/J, characterized by carrying *sec* and *tst*,

has emerged and spread in Japan since 2003 [25]; therefore, it is noteworthy that 43.4% of ST8-

IV in this study were estimated as CA-MRSA/J. In addition, there were four strains that carried

both *LukF/SV* and ACME in *sec* and *tst*-negative ST8-IV, with 4.8% of ST8-IV estimated as

USA300. The characteristics of ST8-IV, other than CA-MRSA/J and USA300, are presented in

Table S3. Of ST8-IV other than CA-MRSA/J and USA300, 83.7% carried *sep* and *ant(9)-Ia*;

88.4%/88.4% in CLSI/EUCAST criteria showed levofloxacin-resistance; 83.7%/86.0% showed

erythromycin-resistance and 86.0% had macrolide resistance genes; 76.9% were detected in

Western Japan. Therefore, there is a possibility that a novel ST8-IV clone has emerged and

spread in Western Japan.

This study had several limitations. First, the impact of changes in SCC*mec* type on the

clinical course is unknown because we did not collect the information on patient backgrounds,

such as age, underlying diseases, as well as severity and prognosis of BSI. Second, we evaluated

the diversity of each MRSA clone based on patterns of drug-resistance and virulence genes.

Identification of diversity in the same clone was not the purpose of this study; pulsed-field gel

electrophoresis and spa typing are needed for detailed analysis. Third, our analyses differed from

those used in previous Japanese surveillance programs, as this is the first WGS. In addition, the

backgrounds of participating medical institutions in this surveillance are different from those of

previous Japanese programs. The participating medical institutions in this study have in-house

microbiology laboratories, whereas those in the previous study outsourced microbiological

testing [15]. Therefore, it is necessary to continue this surveillance to validate changes in MRSA.

Conclusion

This study revealed that SCC*mec* type IV clones replaced SCC*mec* type II in MRSA BSI.

However, the characteristics of the major clones in Japanese SCC*mec* type IV were different

from those in other countries, with a low prevalence of *LukF/PV* and ACME. This study also

indicated that the three main types of SCC*mec* type IV clones, CC1-IV, CA-MRSA/J, and ST8-

IV other than CA-MRSA/J and USA300, have spread throughout Japan, although there were

regional differences.

Conflicts of interest

The authors have no conflicts of interest directly relevant to the content of this article.

Funding

This work was supported by the Japanese Association for Infectious Diseases, Grant for Clinical

Research Promotion [the 1st (2018)]. Taiga Miyazaki, a member of the Committee for Clinical

Research Promotion of the Japanese Association for Infectious Diseases, advised on study design,

sample collection, and manuscript preparation. The funders had no role in the analysis or the

decision to publish.

277   Acknowledgments

We thank Professor Kazuyoshi Kawakami (Medical Microbiology, Mycology and Immunology,

Tohoku University Graduate School of Medicine) for advice on study design and sample

collection as chair of the Committee for Clinical Research Promotion of the Japanese

Association for Infectious Diseases. We also thank all staff members cooperated in this study at

the Japanese Association for Infectious Diseases, Furano Hospital, Sapporo Medical University

Hospital, Aomori Prefectural Central Hospital, Odate Municipal General Hospital, Fukushima

Medical University, Saitama Medical University International Medical Center, Jikei University

Katsusika Medical Center, Yokohama City University Hospital, Yokohama Municipal Citizen's

Hospital, Yokohama City University Medical Center, Tokyo Bay Urayasu Ichikawa Medical

Center, Showa University Hospital, Tokyo Saiseikai Central Hospital, Hamamatsu University

Hospital, Ishikawa Prefectural Central Hospital, Chuno Kosei Hospital, Asanogawa General

Hospital, Nagaoka Red Cross Hospital, University of Fukui Hospital, Toyama University

Hospital, Nagoya University Hospital, Nagoya City University West Medical Center, Niigata

University Medical & Dental Hospital, Japanese Red Cross Society Suwa Hospital, Daiyukai

General Hospital, Osaka Medical and Pharmaceutical University Hospital, Osaka City General

Hospital, Kobe City Nishi-Kobe Medical Center, Osaka Univerisity Hospital, Kindai University

Hospital, University Hospital Kyoto Prefectural University of Medicine, Nara Prefectural

General Medical Center, Shimane University Hospital, Tottori University Hospital, Ehime

University Hospital, Chikamori Hospital, Uwajima City Hospital, Oita Prefectural Hospital,

Saga-Ken Medical Centre Koseikan, University of The Ryukyus Hospital, Fukuoka University

Hospital, National Hospital Organization Nagasaki Medical Center, Fukuoka Children's Hospital,

Nagasaki Goto Chuoh Hospital, and Nagasaki University Hospital for collection of MRSA

strains, Shuji Miyazaki (Department of Laboratory Medicine, Nagasaki University of Hospital)

for support of the analysis of bacteria, and Editage (www.editage.com) for English language

editing.

Access to Data

The derived data supporting the findings of this study are presented in this paper. WGS data

reported in this study are available in the DDBJ Sequence Read Archive

(https://www.ddbj.nig.ac.jp/dra/index-e.html) under accession number DRA013058.

Contributions

All authors were involved in the study design, acquisition, and interpretation of the data. NK, DS,

KO, and KY were involved in data analysis. NK wrote the original manuscript. All authors

revised the manuscript and have approved the manuscript for publication.

References

[1]   Kern W V., Rieg S. Burden of bacterial bloodstream infection—a brief update on

epidemiology and significance of multidrug-resistant pathogens. Clin Microbiol Infect

2020;26:151–7. doi:10.1016/J.CMI.2019.10.031.

[2]   Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial

Bloodstream Infections in US Hospitals: Analysis of 24,179 Cases from a Prospective

Nationwide Surveillance Study. Clin Infect Dis 2004;39:309–17. doi:10.1086/421946.

[3]   Kourtis AP. Vital Signs: Epidemiology and Recent Trends in Methicillin-Resistant and in

Methicillin-Susceptible Staphylococcus aureus Bloodstream Infections — United States.

MMWR Morb Mortal Wkly Rep 2019;68:214–9. doi:10.15585/MMWR.MM6809E1.

[4]   Naimi TS, LeDell KH, Como-Sabetti K, Borchardt SM, Boxrud DJ, Etienne J, et al.

Comparison of Community- and Health Care–Associated Methicillin-Resistant

Staphylococcus aureus Infection. JAMA 2003;290:2976–84.

doi:10.1001/JAMA.290.22.2976.

[5]   Yamada K, Yanagihara K, Hara Y, Araki N, Harada Y, Morinaga Y, et al. Clinical

Features of Bacteremia Caused by Methicillin-Resistant Staphylococcus aureus in a

Tertiary Hospital. Tohoku J Exp Med 2011;224:61–7. doi:10.1620/TJEM.224.61.

[6]   Kaku N, Yanagihara K, Morinaga Y, Yamada K, Harada Y, Migiyama Y, et al. Influence

of antimicrobial regimen on decreased in-hospital mortality of patients with MRSA

bacteremia. J Infect Chemother 2014;20:350–5. doi:10.1016/j.jiac.2013.12.009.

[7]   Hamada M, Yamaguchi T, Sato A, Ono D, Aoki K, Kajiwara C, et al. Increased Incidence

and Plasma-Biofilm Formation Ability of SCCmec Type IV Methicillin-Resistant

Staphylococcus aureus (MRSA) Isolated From Patients With Bacteremia 2021;11:1.

doi:10.3389/fcimb.2021.602833.

[8]   Kimura Y, Morinaga Y, Akamatsu N, Matsuda J, Yamaryo T, Kawakami K, et al.

Antimicrobial susceptibility and molecular characteristics of methicillin-resistant

Staphylococcus aureus in a Japanese secondary care facility. J Infect Chemother

2016;22:14–8. doi:10.1016/J.JIAC.2015.08.011.

[9]   Schwarz S, Silley P, Simjee S, Woodford N, van Duijkeren E, Johnson AP, et al.

343   Editorial: Assessing the antimicrobial susceptibility of bacteria obtained from animals. J

344   Antimicrob Chemother 2010;65:601–4. doi:10.1093/JAC/DKQ037.

345   [10]   EM100 Connect - CLSI M100 ED31:2021 n.d.

346   http://em100.edaptivedocs.net/GetDoc.aspx?doc=CLSI M100 ED31:2021&scope=user

347   (accessed August 20, 2021).

348   [11]   European Committee on Antimicrobial Susceptibility Testing Breakpoint tables for

349   interpretation of MICs and zone diameters Version 11.0 n.d.

350   https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_11

351   .0_Breakpoint_Tables.pdf (accessed August 20, 2021).

352   [12]   Kaya H, Hasman H, Larsen J, Stegger M, Johannesen TB, Allesøe RL, et al. SCC mec

353   Finder, a Web-Based Tool for Typing of Staphylococcal Cassette Chromosome mec in

354   Staphylococcus aureus Using Whole-Genome Sequence Data. MSphere 2018;3.

355   doi:10.1128/MSPHERE.00612-17.

356   [13]   Tetzschner AMM, Johnson JR, Johnston BD, Lund O, Scheutz F. In Silico Genotyping of

357   Escherichia coli Isolates for Extraintestinal Virulence Genes by Use of Whole-Genome

358   Sequencing Data. J Clin Microbiol 2020;58. doi:10.1128/JCM.01269-20.

359   [14]   Joensen KG, Scheutz F, Lund O, Hasman H, Kaas RS, Nielsen EM, et al. Real-time

360   whole-genome sequencing for routine typing, surveillance, and outbreak detection of

361   verotoxigenic Escherichia coli. J Clin Microbiol 2014;52:1501–10.

362   doi:10.1128/JCM.03617-13.

363   [15]   Miura Y, Yamaguchi T, Nakamura I, Koyama S, Tamai K, Okanda T, et al.

364   Epidemiological Trends Observed from Molecular Characterization of Methicillin-

Resistant *Staphylococcus aureus* Isolates from Blood Cultures at a Japanese University

Hospital, 2012–2015. Microb Drug Resist 2018;24:70–5. doi:10.1089/mdr.2017.0008.

[16] Aung MS, Urushibara N, Kawaguchiya M, Hirose M, Ito M, Habadera S, et al. Clonal

diversity of methicillin-resistant Staphylococcus aureus (MRSA) from bloodstream

infections in northern Japan: Identification of spermidine N-acetyltransferase gene (speG)

in staphylococcal cassette chromosomes (SCCs) associated with type II and IV. J Glob

Antimicrob Resist 2021;24:207–14. doi:10.1016/J.JGAR.2020.12.008.

[17] Leclercq R. Mechanisms of resistance to macrolides and lincosamides: Nature of the

resistance elements and their clinical implications. Clin Infect Dis 2002;34:482–92.

doi:10.1086/324626.

[18] Ono D, Yamaguchi T, Hamada M, Sonoda S, Sato A, Aoki K, et al. Analysis of synergy

between beta-lactams and anti-methicillin-resistant Staphylococcus aureus agents from the

standpoint of strain characteristics and binding action. J Infect Chemother 2019;25:273–

80. doi:10.1016/J.JIAC.2018.12.007.

[19] Davis JS, Hal S van, Tong SYC. Combination Antibiotic Treatment of Serious

Methicillin-Resistant   Staphylococcus aureus Infections. Semin Respir Crit Care

Med 2015;36:003–16. doi:10.1055/S-0034-1396906.

[20] Nakaminami H, Takadama S, Ito A, Hasegawa M, Jono C, Noguchi M, et al.

Characterization of SCCmec type IV methicillin-resistant Staphylococcus aureus clones

increased in Japanese hospitals. J Med Microbiol 2018;67:769–74.

doi:10.1099/JMM.0.000735.

[21] Osaka S, Okuzumi K, Koide S, Tamai K, Sato T, Tanimoto K, et al. Genetic shifts in

methicillin-resistant Staphylococcus aureus epidemic clones and toxin gene profiles in

Japan: comparative analysis among pre-epidemic, epidemic and post-epidemic phases. J

Med Microbiol 2018;67:392–9. doi:10.1099/JMM.0.000687.

[22] Coombs GW, Monecke S, Pearson JC, Tan H-L, Chew Y-K, Wilson L, et al. Evolution

and diversity of community-associated methicillin-resistant Staphylococcus aureus in a

geographical region. BMC Microbiol 2011 111 2011;11:1–12. doi:10.1186/1471-2180-11-

215.

[23] Earls MR, Shore AC, Brennan GI, Simbeck A, Schneider-Brachert W, Vremerǎ T, et al. A

novel multidrug-resistant PVL-negative CC1-MRSA-IV clone emerging in Ireland and

Germany likely originated in South-Eastern Europe. Infect Genet Evol 2019;69:117–26.

doi:10.1016/j.meegid.2019.01.021.

[24] Kawamura K, Kitaoka K, Kimura K, Wachino J, Kondo T, Iinuma Y, et al. Spread of seb-

Positive Methicillin-Resistant Staphylococcus aureus SCCmec Type II-ST764 Among

Elderly Japanese in Nonacute Care Settings. Https://HomeLiebertpubCom/Mdr

2019;25:915–24. doi:10.1089/MDR.2018.0337.

[25] Iwao Y, Ishii R, Tomita Y, Shibuya Y, Takano T, Hung WC, et al. The emerging ST8

methicillin-resistant Staphylococcus aureus clone in the community in Japan: associated

infections, genetic diversity, and comparative genomics. J Infect Chemother 2012;18:228–

40. doi:10.1007/S10156-012-0379-6.

Figure Legends

Figure 1. The major clones in Japan

The major clones in Japan (A) and each region (B) were determined by a combination of

sequence type (ST) and SCC*mec* type.

MRSA, methicillin-resistant *Staphylococcus aureus*; ST, sequence type; CC, clonal complex

(A)

Breakdown of others

ST	SCC*mec*	%
CC1 other than ST1 and ST2725	IV	1.9%
ST5	IV	1.5%
CC5 other than ST5 and ST764	II	1.1%
	IV	0.7%
ST8	I	0.9%
	II	1.5%
	IX	0.4%
CC8 other than ST8	IV	1.9%
Other STs	IV	1.9%
	V	1.5%

Figure 1. Combination of Sequence type and SCC*mec* type
A percentage of ST and SCC*mec* type in Japan (A) and each region (B).
MRSA, methicillin-resistant *Staphylococcus aureus*; ST, sequence type; CC, clonal complex

Table 1. Characteristics of the major clones

	ST8-IV	ST1-IV	ST2725-IV	ST764-II	ST5-II
	(n = 83)	(n = 80)	(n = 26)	(n = 22)	(n = 21)
Patient background					
Outpatient	21.7%	23.8%	19.2%	13.6%	-
Inpatient within 48 h of hospitalization	16.9%	13.8%	19.2%	13.6%	28.6%
Inpatient after 48 h of hospitalization	60.2%	62.5%	61.5%	72.7%	71.4%
Unknown	1.2%	-	-	-	-
Drug resistance rate in CLSI/EUCAST					
Oxacillin	96.4 / 96.4	88.8 / 88.8	88.5 / 88.5	100 / 100	100 / 100
Cefoxitin	96.4 / 96.4	97.5 / 97.5	92.3 / 92.3	100 / 100	100 / 100
Levofloxacin	55.4 / 56.6	100 / 100	100 / 100	100 / 100	100 / 100
Erythromycin	59.0 / 61.4	93.8 / 93.8	100 / 100	100 / 100	100 / 100
Clindamycin	44.6 / 45.8	3.8 / 5.0	3.8 / 3.8	100 / 100	85.7 / 85.7
Minocycline	0.0 / 30.1	0.0 / 6.3	0.0 / 3.8	4.5 / 100	4.8 / 71.4
Trimethoprim / Sulfamethoxazole	0.0 / 0.0	0.0 / 0.0	0.0 / 0.0	0.0 / 0.0	0.0 / 0.0
Vancomycin	1.2 / 2.4	0.0 / 1.3	0.0 / 3.8	0.0 / 0.0	0.0 / 0.0
Teicoplanin	0.0 / 1.2	1.3 / 1.3	0.0 / 0.0	0.0 / 0.0	0.0 / 0.0
Linezolid	1.2 / 1.2	1.3 / 1.3	3.8 / 3.8	4.5/ 4.5	0.0 / 0.0

SCCmec, staphylococcal cassette chromosome mec; ST, sequence type; CLSI, Clinical and Laboratory Standards Institute; EUCAST, European Committee on Antimicrobial Susceptibility Testing

Table 2. Antimicrobial susceptibility of MRSA strains

MIC$_{50}$ / MIC$_{90}$	ST8-IV (n = 83)	ST1-IV (n = 80)	ST2725-IV (n = 26)	ST764-II (n = 22)	ST5-II (n = 21)
Ampicillin	≧32 / ≧32	≧32 / ≧32	≧32 / ≧32	8 / 16	≧32 / ≧32
Oxacillin	≧8 / ≧8	≧8 / ≧8	≧8 / ≧8	≧8 / ≧8	≧8 / ≧8
Cefoxitin	8 / 8	8 / 16	8 / 16	≧32 / ≧32	≧32 / ≧32
Cefazolin	4 / 16	4 / 8	2 / 16	≧32 / ≧32	≧32 / ≧32
Imipenem	≦0.25 / ≦0.25	≦0.25 / ≦0.25	0.25 / 0.5	≧32 / ≧32	≧32 / ≧32
Meropenem	1 / 4	≦0.25 / 1	1 / 1	16 / ≧32	16 / ≧32
Levofloxacin	4 / 8	≧32 / ≧32	16 / ≧32	≧32 / ≧32	≧32 / ≧32
Erythromycin	≧16 / ≧16	≧16 / ≧16	≧16 / ≧16	≧16 / ≧16	≧16 / ≧16
Clindamycin	≦0.125 / ≧16	≦0.125 / ≦0.125	≦0.125 / ≦0.125	≧16 / ≧16	≧16 / ≧16
Minocycline	≦0.25 / 8	≦0.25 / ≦0.25	≦0.25 / ≦0.25	8 / 8	8 / 8
Trimethoprim / Sulfamethoxazole	≦0.5/9.5 / ≦0.5/9.5	≦0.5/9.5 / ≦0.5/9.5	≦0.5/9.5 / ≦0.5/9.5	≦0.5/9.5 / ≦0.5/9.5	≦0.5/9.5 / ≦0.5/9.5
Vancomycin	≦0.25 / 1	≦0.25 / 1	≦0.25 / 2	1 / 1	1 / 2
Teicoplanin	≦0.25 / ≦0.25	≦0.25 / 1	both ≦0.25	≦0.25 / ≦0.25	≦0.25 / 1
Linezolid	2/ 2	2/ 2	2/ 2	1 / 2	2 / 2
Daptomycin	≦0.25 / 1	≦0.25 / 1	≦0.25 / 0.5	≦0.25 / 1	≦0.25 / 2
Arbekacin	4 / ≧16	2 / 8	2 / 8	4 / 8	4 / ≧16

MIC, minimum inhibitory concentration; ST, sequence type

Table 3. The positive rate for drug-resistance genes

	ST8-IV	ST1-IV	ST2725-IV	ST764-II	ST5-II
	(n = 83)	(n = 80)	(n = 26)	(n = 22)	(n = 21)
Aminoglycoside-resistance gene	92.8%	95.0%	96.2%	100%	100%
aac(6')-aph(2'')	56.6%	8.8%	11.5%	81.8%	42.9%
aaD	27.7%	1.3%	-	40.9%	85.7%
ant(6)-Ia	2.4%	-	-	4.5%	-
ant(9)-Ia	45.8%	95.0%	96.2%	100%	100%
aph(3')-III	2.4%	-	-	-	-
Beta-lactamase gene *blaZ*	97.6%	98.8%	92.3%	-	71.4%
Chloramphenicol-resistance gene, *cat(pC221)*	-	-	-	4.5%	-
Fosfomycin-resistance gene	6.0%	-	-	40.9%	4.8%
fosB4	-	-	-	4.5%	4.8%
fosD	6.0%	-	-	40.9%	-
Macrolide-resistance gene	56.6%	93.8%	100%	100%	100%
erm(A)	47.0%	93.8%	96.2%	100%	100%
erm(B)	-	1.3%	-	4.5%	-
erm(C)	8.4%	1.3%	4.4%	4.5%	-
mph(C)	2.4%	-	-	4.5%	-
msr(A)	2.4%	-	-	4.5%	-
Methicillin-resistance gene, *mecA*	100%	100%	100%	100%	100%
Tetracycline-resistance gene	28.9%	-	3.8%	100%	76.2%
tet(K)	2.4%	-	-	4.5%	-
tet(M)	26.5%	-	3.8%	100%	76.2%
tet(S/M)	24.1%	-	-	100%	57.1%
Trimethoprim-resistance gene, *dfrG*	1.2%	-	-	-	-

ST, sequence type

Table 4. The positive rate for virulence genes

	ST8-IV	ST1-IV	ST2725-IV	ST764-II	ST5-II
	(n = 83)	(n = 80)	(n = 26)	(n = 22)	(n = 21)
Exoenzyme genes					
aur	100%	100%	100%	100%	100%
splA	96.4%	98.8%	96.2%	100%	100%
splB	94.0%	98.8%	96.2%	100%	100%
splE	47.0%	91.3%	96.2%	-	-
Toxin genes					
edinA	18.1%	-	-	-	-
hlgA	98.8%	100%	96.2%	100%	95.2%
hlgB	100%	100%	100%	100%	100%
hlgC	86.7%	100%	100%	100%	100%
LukD	97.6%	100%	100%	100%	95.2%
LukE	98.8%	100%	100%	100%	95.2%
LukF-PV	6.0%	-	-	-	-
sea	4.8%	88.8%	80.8%	-	4.8%
seb	1.2%	-	3.8%	86.4%	9.5%
sec	44.6%	-	3.8%	13.6%	61.9%
seg	-	-	-	95.5%	81.0%
seh	-	100%	96.2%	-	4.8%
sei	-	-	-	95.5%	100%
sek	6.0%	85.0%	80.8%	13.6%	-
sel	39.8%	-	-	13.6%	71.4%
sem	-	-	-	100%	100%
sen	-	-	-	100%	90.5%
seo	-	-	-	100%	95.2%
sep	67.5%	-	-	9.1%	28.6%
seq	7.2%	85.0%	80.8%	13.6%	4.8%

seu	-	-	-	100%	85.7%
tst	44.6%	3.8%	3.8%	13.6%	66.7%
Other					
ACME	6.0%	1.3%	-	31.8%	-
sak	94.0%	98.8%	100%	72.7%	85.7%
scn	96.4%	98.8%	100%	86.4%	85.7%

ST, sequence type